For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Kiniksa Pharmaceuticals International, plc (KNSA) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Kiniksa Pharmaceuticals International, plc is a global biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies for patients with serious unmet medical needs, particularly in cardiovascular and inflammatory diseases. Its lead product, ARCALYST (rilonacept), is an interleukin-1 inhibitor approved as the first and only FDA-approved treatment for recurrent pericarditis, an inflammatory cardiovascular condition causing debilitating chest pain and inflammation. The company advances a robust pipeline of clinical-stage assets, including vixarelimab, a monoclonal antibody in Phase 2b trials for prurigo nodularis, a chronic inflammatory skin disease, and KPL-387, advancing toward Phase 2/3 trials in recurrent pericarditis for potential monthly dosing. Kiniksa emphasizes immune modulation therapies with strong biologic rationale, targeting underserved conditions across multiple therapeutic categories. Through strategic partnerships, such as collaborations for commercialization in the Asia Pacific region and licensing agreements for global development, Kiniksa expands access to its innovative treatments worldwide. Founded in 2015, the company is headquartered in Hamilton, Bermuda, and led by a seasoned leadership team focused on patient-centric innovation in biopharmaceuticals.
Earnings Schedule
Checked daily · calendar updated Aug 4| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| Jul 28, 2026 | $0.28 | $0.30 +7.1% | — | — |
| Jul 15, 2026 | $3.14 | $2.81 -10.5% | — | — |
| Apr 28, 2026 | $0.16 | $0.27 +68.8% | — | — |
| Feb 24, 2026 | $0.40 | $0.17 -57.5% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Jul 31, 2026 | 4 | View |
| Jul 29, 2026 | 144 | View |
| Jul 29, 2026 | 144 | View |
| Jul 29, 2026 | SCHEDULE 13G | View |
| Jul 28, 2026 | 10-Q | View |
| Jul 28, 2026 | 8-K | View |
| Jul 6, 2026 | 4 | View |
| Jul 6, 2026 | 3 | View |
| Jun 2, 2026 | 4 | View |
| Jun 2, 2026 | 4 | View |
| Jun 2, 2026 | 4 | View |
| Jun 2, 2026 | 4 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Aug 4, 2026 2:40am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 0.75
Total Equity: $567.61M
Shares: 78,979,030
Total Debt: $0.00
Cash: $165.60M
EBITDA: $78.78M
Total Debt: $0.00
Cash: $165.60M
Revenue: $677.56M
Revenue: $677.56M
Revenue: $677.56M
Total Equity: $567.61M
Tax Rate: 33.6%
Equity: $567.61M
Total Debt: $0.00
Cash: $165.60M
Current Liabilities: $139.18M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $567.61M
Shares: 78,979,030
Shares: 78,979,030
CapEx: -$1.57M
Shares: 78,979,030
Stock Price: $73.41
Net Income: $59.01M
Income Statement (Annual)
Last updated: Aug 4, 2026 2:40am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $220.2M | $270.3M | $423.2M | $677.6M |
| Cost of Revenue | $9.1M | $22.9M | $33.4M | $60.9M | $77.7M |
| Gross Profit | — | $197.3M | $236.9M | $362.3M | $599.9M |
| Operating Expenses | $185.2M | $187.5M | $262.0M | $407.9M | $522.7M |
| Operating Income | -$156.6M | $9.8M | -$25.2M | -$45.6M | $77.2M |
| Net Income | -$157.9M | $183.4M | $14.1M | -$43.2M | $59.0M |
| EBITDA | -$154.3M | $12.2M | -$22.9M | -$43.9M | $78.8M |
| EPS | $-2.30 | $2.64 | $0.20 | $-0.60 | $0.80 |
| EPS (Diluted) | $-2.30 | $2.60 | $0.20 | $-0.60 | $0.75 |
Balance Sheet (Annual)
Last updated: Aug 4, 2026 2:40am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $122.5M | $122.7M | $108.0M | $183.6M | $165.6M |
| Total Current Assets | $196.4M | $243.1M | $276.3M | $331.8M | $527.2M |
| Total Assets | $232.8M | $459.7M | $526.3M | $580.6M | $763.6M |
| Current Liabilities | $44.8M | $47.1M | $63.7M | $100.6M | $139.2M |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $47.8M | $63.5M | $87.5M | $142.1M | $196.0M |
| Total Equity | $185.0M | $396.1M | $438.8M | $438.4M | $567.6M |
| Retained Earnings | -$675.4M | -$492.0M | -$478.0M | -$521.1M | -$462.1M |
Cash Flow (Annual)
Last updated: Aug 4, 2026 2:40am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$126.3M | $5.8M | $13.3M | $25.7M | $138.0M |
| Capital Expenditure | $-415,000 | $-105,000 | $-130,000 | $-277,000 | -$1.6M |
| Free Cash Flow | -$126.7M | $5.7M | $13.2M | $25.4M | $136.4M |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | — | — | — | — | — |
Growth Trends (YoY %)
Last updated: Aug 4, 2026 2:40am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | +22.7% | +56.6% | +60.1% |
| Gross Profit Growth | — | +20.1% | +53.0% | +65.6% |
| Operating Income Growth | +106.2% | -357.8% | -81.0% | +269.3% |
| Net Income Growth | +216.1% | -92.3% | -406.7% | +236.6% |
| EBITDA Growth | +107.9% | -287.7% | -92.2% | +279.4% |
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Narrative Economics
market-narrative step).
Claude Reading
ai-findings step) when a report is run on this ticker.
GPT Reading
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.
Advanced Analysis Forensic deep-dive · three lenses
Character & Durability Scorecard
ext-scorecard step) when a report is run on this ticker.